Connect with us

Hi, what are you looking for?

Daily Market SolutionDaily Market Solution

Investing

Biden administration to release list of drugs to Medicare recipients for $2, Axios reports

(Reuters) – The U.S. government will be releasing a preliminary list of generic drugs that would be made available to recipients of the Medicare program for no more than $2, Axios reported on Wednesday citing U.S. officials.

The report added drugs on the list will not be subject to requirements such as prior authorization or quantity limits.

The government will ask for feedback on its initial list of 101 generic drugs which will cover common prescriptions such as penicillin, metformin, lithium and albuterol asthma inhalers, according to the Axios report.

It would also include common drugs for high cholesterol, high blood pressure and other chronic conditions. The program is not expected to start until January 2027, the report said.

The Centers for Medicare & Medicaid Services did not immediately respond to a Reuters request for comment.

 

 

This post appeared first on investing.com







    You May Also Like

    Editor's Pick

    Extremist supporters of former president Donald Trump are lashing out online against Usha Vance, the wife of Trump’s running mate, Sen. J.D. Vance (R-Ohio),...

    Investing

    Australia is home to a thriving tech sector with investment opportunities across a variety of subsectors. The tech sector contributed about AU$167 billion to...

    Editor's Pick

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Investing

    Overview Energy Fuels (TSX:EFR,NYSE:UUUU) has been the largest producer of uranium in the United States and an emerging producer of rare earth elements (REEs)....

    Disclaimer: Dailymarketsolution.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 dailymarketsolution.com